Caterina et al reported that administration of Toll-like receptor 9 (TLR9) agonists directly to mouse lesions significantly impaired local tumor growth, with the therapeutic effect extending to the untreated lesions on the opposite side. This evidence concerns the gene TLR9 and neoplasm.